NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly earnings results on February 18, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.63, missing the consensus estimate of $-0.38 by $0.25 per share. Revenue came in at $32.0K, missing the estimate of $4.3M.
NewAmsterdam Pharma's stock moved following the earnings release. The stock currently trades at $34.30 with a market capitalization of $4.1B.